Severe covid-19 - Open Access .click

Results 11 to 20 of about 2,311,361 (335)

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Lancet, The, 2020
Background No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human ...
Ye-ming Wang +45 more
semanticscholar +3 more sources

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Nature, 2020
Recent studies have provided insights into the pathogenesis of coronavirus disease 2019 (COVID-19) 1 – 4 . However, the longitudinal immunological correlates of disease outcome remain unclear.
C. Lucas +100 more
semanticscholar +3 more sources

Genomewide Association Study of Severe Covid-19 with Respiratory Failure

New England Journal of Medicine, 2020
Background There is considerable variation in disease behavior among patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19). Genomewide association analysis may allow
D. Ellinghaus +145 more
semanticscholar +3 more sources

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

New England Journal of Medicine, 2021
Background Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels.
I. Rosas +22 more
semanticscholar +3 more sources

Inflammasome activation at the crux of severe COVID-19

Nature Reviews Immunology, 2021
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), results in life-threatening disease in a minority of patients, especially elderly people and those with co-morbidities such as obesity and diabetes.
Setu M. Vora, J. Lieberman, Hao Wu
semanticscholar +3 more sources

Clinical utility of cardiac troponin measurement in COVID-19 infection [PDF]

, 2020
The novel coronavirus SARS-CoV-2 causes the disease COVID-19, a severe acute respiratory syndrome. COVID-19 is now a global pandemic and public health emergency due to rapid human-to-human transmission.
Gaze, D.C., Gaze, D.C.
core +1 more source

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

New England Journal of Medicine, 2020
Background No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. Methods We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection,
B. Cao +64 more
semanticscholar +1 more source

Severe superior mesenteric vein thrombosis after COVID‐19 mRNA vaccination

Clinical Case Reports, 2023
Key Clinical Message Venous thrombosis is a rare occurrence following the administration of the COVID‐19 mRNA vaccine. The occurrence of superior mesenteric vein (SMV) is even more rare.
Takahiro Kubo, Hideto Kawaratani, Hitoshi Yoshiji +2 more
doaj +1 more source

RISK FACTORS OF TRANSMISSION OF CORONAVIRUS DISEASE 2019 (COVID-19) IN CHILDREN: A REVIEW [PDF]

, 2021
Introduction: The transmission of Coronavirus Disease 2019 (COVID-19) in children in the world is still high, especially from the environment where children live and play.
Bekti Prasetyo, Yoyok +4 more
core +1 more source

Effective treatment of severe COVID-19 patients with tocilizumab

Proceedings of the National Academy of Sciences of the United States of America, 2020
Significance In patients with coronavirus disease 2019, a large number of T lymphocytes and mononuclear macrophages are activated, producing cytokines such as interleukin-6 (IL-6), which bind to the IL-6 receptor on the target cells, causing the cytokine
Xiaoling Xu +12 more
semanticscholar +1 more source

medicine
covid-19
3. good health

sars-cov-2
humans
covid‐19

pandemics
pneumonia, viral
biology